[1] Matos MJ.  Learning from nature: the role of albumin in drug delivery[J]. Future Med Chem, 2018, 10(9): 983-985.   doi: 10.4155/fmc-2018-0053
[2] Lau J, Jacobson O, Niu G, et al.  Bench to bedside: albumin binders for improved cancer radioligand therapies[J]. Bioconjug Chem, 2019, 30(3): 487-502.   doi: 10.1021/acs.bioconjchem.8b00919
[3] Battogtokh G, Kang JH, Ko YT.  Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug[J]. Eur J Pharm Biopharm, 2015, 96: 96-105.   doi: 10.1016/j.ejpb.2015.07.013
[4] Gapizov SS, Petrovskaya LE, Shingarova LN, et al.  Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein[J]. Biotechnol Appl Biochem, 2019, 66(4): 617-625.   doi: 10.1002/bab.1762
[5] Kaeppeli SAM, Jodal A, Gotthardt M, et al.  Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting[J]. Mol Pharm, 2019, 16(9): 3760-3769.   doi: 10.1021/acs.molpharmaceut.9b00271
[6] Zhang JJ, Wang H, Jacobson O, et al.  Safety, pharmacokinetics, and dosimetry of a long-acting radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in patients with advanced metastatic neuroendocrine tumors[J]. J Nucl Med, 2018, 59(11): 1699-1705.   doi: 10.2967/jnumed.118.209841
[7] Kelly JM, Amor-Coarasa A, Ponnala S, et al.  Albumin-binding PSMA ligands: implications for expanding the therapeutic window[J]. J Nucl Med, 2019, 60(5): 656-663.   doi: 10.2967/jnumed.118.221150
[8]

Wen XJ, Xu PF, Shi MQ, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics[J/OL]. Theranostics, 2022, 12(1): 422−433[2022-04-19]. https://www.thno.org/v12p0422.htm. DOI: 10.7150/thno.68182.
[9]

Deberle LM, Tschan VJ, Borgna F, et al. Albumin-binding PSMA radioligands: impact of minimal structural changes on the tissue distribution profile[J/OL]. Molecules, 2020, 25(11): 2542[2022-04-19]. https://www.mdpi.com/1420-3049/25/11/2542. DOI: 10.3390/molecules25112542.
[10] Chen HJ, Jacobson O, Niu G, et al.  Novel "add-on" molecule based on Evans blue confers superior pharmacokinetics and transforms drugs to theranostic agents[J]. J Nucl Med, 2017, 58(4): 590-597.   doi: 10.2967/jnumed.116.182097
[11] Long X, Zhang JJ, Zhang DM, et al.  Microsurgery guided by sequential preoperative lymphography using 68Ga-NEB PET and MRI in patients with lower-limb lymphedema[J]. Eur J Nucl Med Mol Imaging, 2017, 44(9): 1501-1510.   doi: 10.1007/s00259-017-3676-6
[12] Peng L, Zhao JL, Mao F, et al.  68Ga-NEB PET/CT can be a new method for diagnosing chylous fistula: case reports of a rare complication after breast cancer surgery[J]. Medicine, 2020, 99(29): e21201-.   doi: 10.1097/MD.0000000000021201
[13] Niu G, Lang LX, Kiesewetter DO, et al.  In vivo labeling of serum albumin for PET[J]. J Nucl Med, 2014, 55(7): 1150-1156.   doi: 10.2967/jnumed.114.139642
[14] Wang Y, Lang LX, Huang P, et al.  In vivo albumin labeling and lymphatic imaging[J]. Proc Natl Acad Sci U S A, 2015, 112(1): 208-213.   doi: 10.1073/pnas.1414821112
[15]

Chen HJ, Tong X, Lang LX, et al. Quantification of tumor vascular permeability and blood volume by positron emission tomography[J/OL]. Theranostics, 2017, 7(9): 2363−2376[2022-04-19]. https://www.thno.org/v07p2363.htm. DOI: 10.7150/thno.19898.
[16] Dumelin CE, Trüssel S, Buller F, et al.  A portable albumin binder from a DNA-encoded chemical library[J]. Angew Chem, 2008, 120(17): 3240-3245.   doi: 10.1002/ange.200704936
[17] Müller C, Struthers H, Winiger C, et al.  DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice[J]. J Nucl Med, 2013, 54(1): 124-131.   doi: 10.2967/jnumed.112.107235
[18] Kuo HT, Merkens H, Zhang ZX, et al.  Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies[J]. Mol Pharm, 2018, 15(11): 5183-5191.   doi: 10.1021/acs.molpharmaceut.8b00720
[19] Wen XJ, Shi CR, Xu D, et al.  Radioiodinated portable albumin binder as a versatile agent for in vivo imaging with single-photon emission computed tomography[J]. Mol Pharm, 2019, 16(2): 816-824.   doi: 10.1021/acs.molpharmaceut.8b01116
[20] Wen XJ, Shi CR, Yang L, et al.  A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL[J]. Eur J Nucl Med Mol Imaging, 2022, 49(2): 503-516.   doi: 10.1007/s00259-021-05447-4
[21] Kramer V, Fernández R, Lehnert W, et al.  Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC[J]. Eur J Nucl Med Mol Imaging, 2021, 48(3): 893-903.   doi: 10.1007/s00259-020-05022-3
[22] Kuo HT, Lin KS, Zhang ZX, et al.  177Lu-labeled albumin-binder-conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio[J]. J Nucl Med, 2021, 62(4): 521-527.   doi: 10.2967/jnumed.120.250738
[23] Jonsson A, Dogan J, Herne N, et al.  Engineering of a femtomolar affinity binding protein to human serum albumin[J]. Protein Eng Des Sel, 2008, 21(8): 515-527.   doi: 10.1093/protein/gzn028
[24] Orlova A, Jonsson A, Rosik D, et al.  Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule–albumin-binding domain fusion protein[J]. J Nucl Med, 2013, 54(6): 961-968.   doi: 10.2967/jnumed.112.110700
[25] Garousi J, Von Witting E, Borin J, et al.  Radionuclide therapy using ABD-fused ADAPT scaffold protein: proof of principle[J]. Biomaterials, 2021, 266: 120381-.   doi: 10.1016/j.biomaterials.2020.120381
[26] Callmann CE, LeGuyader CLM, Burton ST, et al.  Antitumor activity of 1, 18-octadecanedioic acid-paclitaxel complexed with human serum albumin[J]. J Am Chem Soc, 2019, 141(30): 11765-11769.   doi: 10.1021/jacs.9b04272
[27] Zhang JH, Dong YZ, Ju DW, et al.  Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates[J]. Bioorg Med Chem, 2021, 44: 116291-.   doi: 10.1016/j.bmc.2021.116291
[28] Wolff M, Schüler A, Gast K, et al.  Self-assembly of exendin-4-derived dual peptide agonists is mediated by acylation and correlated to the length of conjugated fatty acyl chains[J]. Mol Pharm, 2020, 17(3): 965-978.   doi: 10.1021/acs.molpharmaceut.9b01195
[29] Han J, Huang X, Sun LD, et al.  Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity[J]. Biochem Pharmacol, 2013, 86(2): 297-308.   doi: 10.1016/j.bcp.2013.05.012
[30] Lee JY, Park T, Hong E, et al.  Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity[J]. Biomaterials, 2020, 257: 120250-.   doi: 10.1016/j.biomaterials.2020.120250
[31] Zhang P, Xu MX, Ding J, et al.  Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy[J]. Eur J Nucl Med Mol Imaging, 2022, 49(6): 1985-1996.   doi: 10.1007/s00259-021-05591-x
[32]

国家药典委员会. 中华人民共和国药典2020年版(二部)[M]. 北京: 中国医药科技出版社, 2020: 1897−1898.

Chinese Pharmacopoeia Commission. China Pharmacopoeia 2020 (Volume Ⅱ)[M]. Beijing: China Medical Science Press, 2020: 1897−1898.
[33] Hofman MS, Violet J, Hicks RJ, et al.  [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19(6): 825-833.   doi: 10.1016/S1470-2045(18)30198-0
[34] Rahbar K, Ahmadzadehfar H, Kratochwil C, et al.  German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients[J]. J Nucl Med, 2017, 58(1): 85-90.   doi: 10.2967/jnumed.116.183194
[35] Zang J, Fan XR, Wang H, et al.  First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2019, 46(1): 148-158.   doi: 10.1007/s00259-018-4096-y
[36] Liu QX, Cheng YJ, Zang J, et al.  Dose escalation of an Evans blue-modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors[J]. Eur J Nucl Med Mol Imaging, 2020, 47(4): 947-957.   doi: 10.1007/s00259-019-04530-1
[37] Hänscheid H, Hartrampf PE, Schirbel A, et al.  Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC[J]. Eur J Nucl Med Mol Imaging, 2021, 48(8): 2566-2572.   doi: 10.1007/s00259-020-05177-z